
Antares Pharma, Inc. ATRS
Antares Pharma, Inc. Gross Profit 2011-2026 | ATRS
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Antares Pharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 86.5 M | 73.4 M | 32.5 M | 27 M | 23.4 M | 26.2 M | 15.3 M | 11.4 M | 13.1 M | 9.66 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 86.5 M | 9.66 M | 31.8 M |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
2.68 B | $ 60.84 | 0.76 % | $ 12.1 B | ||
|
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | ||
|
ICU Medical
ICUI
|
822 M | $ 122.4 | -0.48 % | $ 3.02 B | ||
|
iRhythm Technologies
IRTC
|
527 M | $ 114.08 | -0.07 % | $ 3.65 B | ||
|
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | ||
|
Intuitive Surgical
ISRG
|
6.64 B | $ 428.24 | 0.04 % | $ 153 B | ||
|
Alcon
ALC
|
5.74 B | $ 64.65 | 1.02 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
25.6 M | $ 3.91 | -1.75 % | $ 181 M | ||
|
LeMaitre Vascular
LMAT
|
179 M | $ 99.4 | -0.1 % | $ 2.25 B | ||
|
Masimo Corporation
MASI
|
1 B | $ 178.41 | 0.03 % | $ 9.51 B | ||
|
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
6.84 M | - | - | $ 28.6 M | ||
|
Envista Holdings Corporation
NVST
|
1.49 B | $ 23.9 | 0.21 % | $ 4.02 B | ||
|
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | ||
|
electroCore
ECOR
|
27.8 M | $ 6.3 | -2.02 % | $ 53.4 K | ||
|
Haemonetics Corporation
HAE
|
749 M | $ 57.35 | 0.46 % | $ 2.89 B | ||
|
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
239 M | $ 143.0 | 0.6 % | $ 6.93 B | ||
|
STAAR Surgical Company
STAA
|
182 M | $ 31.91 | -0.31 % | $ 1.58 B | ||
|
STERIS plc
STE
|
2.4 B | $ 216.15 | 0.08 % | $ 21.3 B | ||
|
Teleflex Incorporated
TFX
|
307 M | $ 130.56 | 0.21 % | $ 5.83 B | ||
|
InfuSystem Holdings
INFU
|
80.3 M | $ 8.43 | -2.37 % | $ 174 M | ||
|
Microbot Medical
MBOT
|
117 K | $ 1.92 | 3.69 % | $ 87.9 M | ||
|
Milestone Scientific
MLSS
|
6.41 M | $ 0.34 | -1.02 % | $ 27.9 M | ||
|
Merit Medical Systems
MMSI
|
738 M | $ 62.37 | -0.3 % | $ 3.69 B | ||
|
Utah Medical Products
UTMD
|
5.26 M | $ 63.24 | -0.72 % | $ 205 M | ||
|
West Pharmaceutical Services
WST
|
1.1 B | $ 301.21 | 0.34 % | $ 21.8 B | ||
|
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 10.1 | -3.03 % | $ 2.01 B | ||
|
Retractable Technologies
RVP
|
47 K | $ 0.69 | -0.01 % | $ 20.7 M | ||
|
Pro-Dex
PDEX
|
19.5 M | $ 57.73 | -1.57 % | $ 190 M | ||
|
Predictive Oncology
POAI
|
1.02 M | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
62.1 M | $ 20.76 | -1.42 % | $ 991 M | ||
|
Stereotaxis
STXS
|
17.1 M | $ 1.89 | -2.83 % | $ 172 M | ||
|
Baxter International
BAX
|
3.38 B | $ 17.62 | -0.96 % | $ 9.04 B | ||
|
ResMed
RMD
|
2.02 B | $ 204.91 | 1.21 % | $ 29.9 B | ||
|
AtriCure
ATRC
|
401 M | $ 28.69 | 1.92 % | $ 1.37 B | ||
|
Harvard Bioscience
HBIO
|
49.9 M | $ 5.34 | -3.26 % | $ 237 M | ||
|
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
158 M | $ 10.98 | -0.45 % | $ 449 M | ||
|
Becton, Dickinson and Company
BDX
|
8.29 B | $ 143.99 | -0.33 % | $ 41.4 B | ||
|
Nephros
NEPH
|
11.6 M | $ 3.2 | -4.23 % | $ 34 M | ||
|
OraSure Technologies
OSUR
|
48.2 M | $ 3.04 | 3.05 % | $ 223 M | ||
|
Repligen Corporation
RGEN
|
151 M | $ 106.8 | 3.31 % | $ 6.01 M |